Early trial data supports neurodegenerative disease-modifying drug
Drug Discovery World
MARCH 15, 2024
Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.
Let's personalize your content